The impact of blood eosinophil count and FeNO on benralizumab effectiveness in clinical practice: An ORBE II subanalysis.

Background: The ORBE II study showed the real-world effectiveness of benralizumab in severe eosinophilic asthma (SEA). This subgroup analysis aimed to characterize patients and outcomes based on baseline blood eosinophil count (BEC) and/or fractional exhaled nitric oxide (FeNO) levels.

Methods: In this analysis of the ORBE II retrospective study, SEA patients receiving benralizumab were categorized into subgroups based on individual or combined BEC/FeNO levels, according to the following thresholds: high BEC (hiBEC): ≥300 cells/μL; low BEC (loBEC): <300 cells/μL; high FeNO (hiFeNO): ≥50 ppb; low FeNO (loFeNO): <50 ppb.

Stress Management Program for Scanxiety in People With Advanced Lung Cancer: Intervention Adaptation and Stakeholder Feedback.

Background: Although scanxiety is common and impactful for people with advanced lung cancer, few interventions address this psychosocial concern.

Aims: To create a stress management program for scanxiety.

Methods: We conducted a structured intervention adaptation process guided by the ADAPT-ITT framework.

The dual impact of education and occupation on cognitive functioning in older Mexican adults: A cross-sectional exploratory study.

This research investigated the relationship between cognitive performance and an individual's educational attainment as well as occupational mental demands among Mexican adults aged 50 or older. We hypothesized that cognitively demanding work boosts cognitive performance for older adults regardless of their education level. To test our hypothesis, we analyzed data on 12,939 individuals in the 2012 Mexican Health and Aging Study using a Generalized Linear Model with a Gaussian family and identity link function.

Nivolumab combination therapies in patients with advanced gastric and gastroesophageal junction cancer: the phase II FRACTION gastric cancer study.

Background: Nivolumab-based therapies are efficacious with acceptable safety in patients with gastric cancer (GC) and gastroesophageal junction cancer (GEJC). Novel nivolumab-based combination immunotherapies may offer enhanced efficacy in these indications. FRACTION-GC was a signal-seeking, randomized, open-label, phase II adaptive-design trial assessing efficacy and safety of nivolumab in combination with ipilimumab [cytotoxic T lymphocyte antigen-4 (CTLA-4) antibody], relatlimab (lymphocyte-activation gene 3 antibody), or IDO1i (BMS986205, an indoleamine-2,3-dioxygenase-1 inhibitor) in patients with unresectable, advanced/metastatic GC/GEJC.